4906.5000 65.50 (1.35%)
NSE Jun 27, 2025 15:31 PM
Volume: 113.9K
 

4906.50
1.35%
Motilal Oswal
It had a positive impact of higher offtake of COVID-19 associated drugs in the recent past. The reduction in COVID-19 cases, coinciding with seasonal change, bodes well for a pick-up in the performance of Acute therapies. Bunched-up ANDA launches over the next 12-15 months are expected to improve sales growth as well as profitability of the US business. We have tweaked our FY22E/FY23E EPS estimate by 2%/3% and continue to value ALKEM at 23x 12-months forward earnings to arrive at our TP of INR3,730. We remain positive on the back of robust growth in the DF segment and...
Alkem Laboratories Ltd. is trading below all available SMAs
More from Alkem Laboratories Ltd.
Recommended